Pharmaceutical Executive June 2016

June 2016 | Volume 36, Issue 6
From the Editor
William Looney explores the power of workplace aesthetic on the intangibles of culture, morale — and corporate mission.
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.
The World Medical Innovation Forum presents its second list of breakthrough technologies—this time focused on oncology.
How companies can better integrate valuable data across business functions to meet rising value-chain demands.
There’s a stampede to relate prices to broader health benefits, but little consensus on how to do so, writes Jill Wechsler.
Top officials at EMA push the boat out on drug-pricing views.
Pharm Exec’s 16th annual listing of the top biopharma players points to important transitions taking place in the larger business model.
Biopharma’s diversity commitment remains a work in progress but the benefits—in measurable ROI—are increasingly clear.
A new industry working group explores alternative drug funding options in Europe.
A new prognosis tool for the treatment of MS shows how an accessible visualization of disease state can serve as the threshold for fresh clinical insight.
Do recent trends in the pharma and biotech M&A and equity markets signal a temporary lull — or a permanent drop? Peter Young reports.
Special Sponsored Section
By Pharmaceutical Executive Editors
While the Italian fashion and automotive industries may steal the global thunder, another sector in Italy flourishes beneath the public’s radar. The country’s pharmaceutical industry continues to punche above its weight in many areas and has supported Italy’s national economy through many periods of weakness.
lorem ipsum